Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Material yes or no would most likely need reported. It just reads as though Leo may have been given at the very least an April date that he would receive an answer. Otherwise April will come and go.
I completely agree with the statement as a whole because he already has the trials status's but what I'm saying is that how did Leo know April 1 he would be able to update shareholders in April on Nasdaq events unless he already knew the answer. Just saying it seems like maybe Nasdaq already replied.
Leo reported on April 1 that Cellceutix will provide shareholders with a comprehensive update status on its NASDAQ uplisting in April. The comprehensive update statement sounds like Leo already has uplisting information otherwise he is just hoping to hear back from NASDAQ this month.
Retire your question about why the patient left the trial "prematurely" as you stated has been explained here 50 ways to Sunday with the best possible theory that is humanly possible. Refer back to Karen CA last response and stare at it for awhile. I might add that she left the trial for further treatment because she was well enough to do so.
I'm very bullish on ctix short and longer term. By June Leo will have received Kevetrin good news regarding p21 blood tests at higher dosage also Brilacidin FDA Phase3 blessing. Like the QIDP designation any of the above will launch share price soon.
Me too 1400, added a bit more to my Roth. Hopefully will have some real tax free gains in the near future.
They don't call it March Madness for nothing..
Don't worry next month it'll be Christmas in April in CTIX land.ha
A political connection on board doesn't hurt ether.
Stocks up 300% in three years...whats your next "credibility concern."
Hoping...love this stock and yes hope springs eternal. eom
Sure hope Leo's got a fantastic update for us Monday...Go Rally.
"The new Directors could be named any day".
Yes any day my thoughts exactly!! Thanks familyman for the reply.
Looking forward to the announcement of principles from Leo regarding the completed vetting processes. Quote from Feb5: "The names of the prospective Directors will be submitted to NASDAQ for their vetting process to ensure that the individuals meet the requirements per NASDAQ definitions. We look forward to announcing these people as the processes are completed".
Even though one of Brilacidin's key features listed in cellceutix is "active against gram negative bacteria" someone keeps posting the opposite which is very misleading.
u huh, Just doing my part. Over at Lilly, Dr. Menon played a key role in lead selection and pre-clinical development of Gemzar and Alimta, two anti-cancer drugs which have generated billions of dollars in yearly revenue. In addition, Lilly honored Dr. Menon with the prestigious President’s Recognition Award. See more at Cellceutix.com
Totally agree with having some deal lined up. Leo is not fool hearty and wouldn't risk the embarrassment of being turned down now that the wheels are in motion.
Interesting trade @3.71 for 18000+ shares @ 4.02 pm. Type Form T. Perhaps after hours spread based on news. Just a thought.
This board gives positive reinforcement or the "whiners" would have sold and moved on. Read the CHART, look at the CHART and you will see that Leo is moving this company along nicely.
To say what you want without DD evidence to back it is not prudent.
I noticed the writer of the linked article's primary interests is novel small molecule drugs, next generation vaccines, and cell therapies.
My Comment the following:
"Cellceutix has a robust pipeline of 3 drugs including the cancer drug Kevetrin currently in phase1 cohort10 at Dana Farber Cancer center with some positive results against ovarian cancer. Also a defensin mimetic antibiotic called Brilacidin having finished a very positive phase2b outcome comparing Cubicin 7 day dose regimine against Brilacidin 1 day dose for ABSSSI infection. Brilacidin preparing to start phase3 soon. Also a drug by the name of Prurisol for combating psoriasis. Prurisol is a small molecule that acts through immune modulation and has been seen to have incredible invitro results in clearing psoriasis in mouse models. Prurisol phase2 is set to begin any day"
http://www.fool.com/investing/general/2015/02/01/an-8-billion-hedge-fund-bought-this-extremely-risk.aspx#commentsBoxAnchor
Excellent response smilingra and I agree wholeheartedly. Another thing to remember is that the Brilacidin trial was double blinded, no way to get collusion.
These are stage4 patients who have not responded and have failed multiple other drugs which brought them to the Dana Farber cancer research study, patients if not for the Kevetrin study would have no hope.
Hearing first hand of such a great improvement in the health and quality of life for this once very sick Ovarian cancer patient said to be well enough now to explore further treatment is simply remarkable. More to come I'm pretty sure.
Stage4 end of life cancer patient feeling better, getting stronger, going on hikes and seeing metastatic tumors disappear. Kevetrin is a "miracle" drug.
The delay in meeting with the FDA clearly caught the CEO off guard who had reported November11 they would be meeting in December to discuss with FDA in advancing the clinical development of Brilacidin for ABSSSI as well as Prurisol for treatment of psoriasis. Even though their face to face meeting has been delayed it should happen soon. Brilacidin was given QIDP approval as reported Dec8 which includes fast track and priority review. Brilacidin performed very well in phase2a&2b which showed a one time dose as good or better then 7 day dose of daptomycin in treatment of ABSSSI. Investors get skiddish or impatient sell move on then come back. It will be back up even higher soon. Also cancer drug Kevetrin in phase1 testing was reported to show efficacy against metastasis ovarian cancer as reported in one patient. All good IMO.
Thank You Sox for outlining upcoming kevetrin catalysts. Will also be looking forward to the FDA brilacidin P3 nod.
Thank you ericseb and others for your responses.
I'm not attacking, I started buying in early 2012 at .60 and hold well over 70,000 shares, this is my first OTC bio investment and have been through ups and downs of growing pains. I'm not a shorter or flipper just have short term concerns. Take care my friend.
The QIDP designation for brilacidin thanks to Dr Alexander the new COO was the catalyst for the tremendous price increase since Dec8. This was great "news" that brought many new investors in. FDA brilacidin P3 would have been the next leg up. As far as financing yes they have shelf offering that could cause dilution without a corporate partner. Been through an Aspire deal and saw share price go from 2.20 to 1.60 with a lot of angst from a number of board members. I understand we are farther along in testing and with a multi-billion dollar drug portfolio potential. But in the short term is where I'm concerned. If someone has the answer to this please expound. IMO
Shorts are having a big day.. Negatives from bio conference FDA meeting to discuss Brilacidin Phase3 bottom line meeting went from December to at least 2 more months away. Uplisting went from on Leo's desk and soon to 2015. No discussion's of a partnership. We know Cellceutix is paying for Kevetrin testing and now it appears to have no end in sight. Money will soon become a real issue.IMO... Criticism welcomed.
TOB, thank you for the reply.
My thinking is the ascite fluid build up and speen tumors were brought on by the primary ovarian cancer. The secondary affects responding to Kevetrin after only 3 courses. I thought this trial was reserved for patients that have no other course of action left, if so where did she go or was she well enough after the Kevetrin treatments to again seek a more direct approved ovarian treatment. Just a thought.
Hearing of the patient with stage4 cancer feeling much better, going hiking and no longer needing weekly draining due to ascites fluid build up is incredible. Her spleen tumor disappearing is also a testament that kevetrin works. Just common sense thinking as I'm not in the medical field.
My sharebuilder acct is showing 2.98, called cs and was told they would look into it. My Ameritrade closed correct at 4.30. By looking at other posts this seems to be systemic.
Thank You slcimmuno for pushing up the valuable data. I almost fell out of my seat when reading the 2007 interview with NICHOLAS LANDEKIC. Cellceutix will have some deep pocketed suitors calling.. imo
I like you think the broad scope use of the Brilacidin compound could be mind-boggling. We may have something bigger and farther reaching in use then we can imagine. Let's hope so.
My first thought was license to the huge children toy market. Endless.
Nov. 24 PR. The Company anticipates that the Kevetrin trial is nearing its conclusion with the start of the tenth cohort next month. Cellceutix looks forward to additional data from the trial to add to current information that has been used to form decisions for planned Phase 2/3 trials of Kevetrin.
Since no further mention of cohort 10, Could it be they are now looking at very positive kevetrin data and will leap ahead to announce a planned phase2/3 at January's conference. At least wishful thinking.
Thanks again.
Thanks.
The B-OM study is Brilacidin against a water placebo comparator. Since the study dosage time frame per patient is seven weeks they may see results in March. Not sure if this is a double blind study though.